A Multi-Center, Open-Label, Dose-Expansion Phase Ib Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb): Preliminary Results from CS1001 Monotherapy in Patients (pts) with High-Microsatellite Instability (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

A Multi-Center, Open-Label, and Dose-Expansion Phase Ib Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb): Preliminary Results from CS1001 in Combination with Oxaliplatin and Capecitabine (XELOX) in Patients (pts) with Unresectable, Locally Advanced or Metastatic Gastric and Gastro-Esophageal Junction Carcinoma (GC/GEJ)

A Multi-Center, Open-Label, and Dose-Expansion Phase Ib Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb): Preliminary Results from CS1001 in Combination with Cisplatin and 5-Fluorouracil (CF) Chemotherapy in Patients (pts) with Esophageal Squamous Cell Carcinoma (ESCC)

一项关于抗PD-L1单克隆抗体CS1001的多中心、开放性、剂量扩展lb期临床试验：CS1001联合化疗用于胃癌(GC)/胃食管交界处(GEJ)癌患者一线治疗的初步结果

一项关于抗PD-L1单克隆抗体CS1001的多中心、开放性、剂量扩展Ib期临床试验：CS1001单药治疗不可切除胆管癌或胆囊癌（CC/GBC）患者的初步研究结果

一项比较CS1001联合含铂双药化疗与安慰剂联合含铂双药化疗在IV期非小细胞肺癌受试者中的疗效与安全性的多中心、随机、双盲的III期研究GEMSTONE 302 研究

一项抗PD-L1单克隆抗体CS1001作为巩固治疗在同步/序贯放化疗后未发生疾病进展的、局部晚期/不可切除（III期）的非小细胞肺癌患者中的随机双盲、安慰剂对照的III期研究GEMSTONE 301 研究

一项CS1003 作用于中国晚期实体瘤及淋巴瘤患者的 I 期研究的初步安全性、药代动力学和有效性数据